EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis

Brad H Rovin, Richard Furie, Ana Malvar, Cynthia Aranow, Jose M Pego-Reigosa, Elena Zakharova, Andreas Schwarting, Angela R Jones-Leone, Paula Curtis, Beulah Ji, David A Roth, André van Maurik

Kidney International · 2026-07 · 110 (1) · 214-226

DOI: 10.1016/j.kint.2026.03.017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2026-07. Verfasst von Brad H Rovin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: brad.rovin@osum…. Hauptthemen laut MEDLINE: Lupus Nephritis, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline Biologicals SA, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study evaluated the effects of belimumab versus placebo on biomarker responses and identified predictive biomarkers for kidney response to belimumab in patients with lupus nephritis (LN) receiving different standard therapies. METHODS: BLISS-LN was a Phase 3 study (NCT01639339) of adults with active LN randomized to intravenous belimumab 10 mg/kg or placebo plus standard therapy (cyclophosphamide [CYC] or mycophenolate mofetil [MMF] as initial therapy followed by azathioprine or MMF). Absolute and percentage changes from baseline in immunoglobulins, anti-dsDNA and anti-C1q antibodies, C3 and C4, CD19+ B cells and subsets were assessed through Week 104. Post hoc logistic regression models assessed the association of baseline biomarker levels, and of early changes in biomarkers, with kidney response to belimumab in the overall population at Week 104. RESULTS: Of 446 patients (belimumab: 59 received CYC, 164 received MMF; placebo: 59 received CYC, 164 received MMF), approximately 50-60% had data on treatment at Week 104. At Week 104, numerically greater percentage reductions in IgA, IgM and anti-dsDNA antibodies and plasmablasts, and greater increases in C3 and C4 levels, were observed with belimumab versus placebo. Overall, belimumab reduced total CD19+ B cells and naïve B cells versus placebo. These results were generally consistent in the overall population and within each induction group. Predictors of kidney response observed in belimumab-treated patients included high baseline levels of IgA, anti-C1q antibodies and naïve B cells, low baseline plasmablasts and early decreases from baseline in levels of IgA, IgM and urinary protein to creatinine ratio. CONCLUSIONS: Similar effects of belimumab on biomarker outcomes were observed within the induction groups. Baseline biomarkers and early changes in biomarkers associated with kidney response to belimumab in LN were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsHumansBiomarkersAdultFemaleMaleTreatment OutcomeCyclophosphamideMycophenolic AcidDrug Therapy, CombinationAzathioprineMiddle AgedDouble-Blind MethodAntibodies, AntinuclearComplement C3KidneyComplement C1qYoung Adult

Stichwörter der Autor:innen

B cellsB lymphocytesautoantibodiesbiological therapylupus nephritis

Substanzen

Antibodies, Monoclonal, HumanizedbelimumabBiomarkersImmunosuppressive AgentsCyclophosphamideMycophenolic AcidAzathioprineAntibodies, AntinuclearComplement C3Complement C1q

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: brad.rovin@osumc.edu.
  • Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.
  • Division of Nephrology, Department of Medicine, Fernandez Hospital, Buenos Aires, Argentina.
  • Feinstein Institutes for Medical Research, Institute of Molecular Medicine, Hofstra/Northwell, Manhasset, New York, USA.
  • Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Hospital Meixoeiro, Vigo, Spain; Rheumatology Department, Galicia Sur Health Research Institute and IRIDIS (Investigation in Rheumatology and Immune-…
  • Department of Nephrology, Moscow Botkin Hospital, Moscow, Russia.

Förderung

  • GlaxoSmithKline Biologicals SA
  • GlaxoSmithKline

Zitieren

APA

Rovin, B. H., Furie, R., Malvar, A., Aranow, C., Pego-Reigosa, J. M., Zakharova, E., Schwarting, A., Jones-Leone, A. R., Curtis, P., Ji, B., Roth, D. A., & van Maurik, A. (2026). Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis. Kidney International, 110(1), 214-226. https://doi.org/10.1016/j.kint.2026.03.017

Vancouver

Rovin BH, Furie R, Malvar A, Aranow C, Pego-Reigosa JM, Zakharova E, et al. Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis. Kidney International. 2026;110(1):214-226. doi:10.1016/j.kint.2026.03.017

BibTeX
@article{Rovin2026,
  author = {Rovin, Brad H and Furie, Richard and Malvar, Ana and Aranow, Cynthia and Pego-Reigosa, Jose M and Zakharova, Elena and Schwarting, Andreas and Jones-Leone, Angela R and Curtis, Paula and Ji, Beulah and Roth, David A and van Maurik, André},
  title = {Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis},
  journal = {Kidney International},
  year = {2026},
  volume = {110},
  number = {1},
  pages = {214--226},
  doi = {10.1016/j.kint.2026.03.017}
}
Kostenlos starten →